Sandoz targets mid-to-high single-digit net sales CAGR in 2025-30, core EBITDA margin 25%-27% by 2030

• Sandoz reaffirmed its outlook to 2028, unchanged, as it unveiled a new mid-term forecast for 2025-2030.
• Targets mid-to-high single-digit CAGR in net sales at constant currencies from 2025-2030.
• Sees core EBITDA margin at 25%-27% by 2030.
• Bio100 ambition aims to more than double net sales from 2025 to 2035.
• Plans core EBITDA margin above 30% by 2035, supported by expanding its biosimilar portfolio to more than 100 by 2040.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2394968_en) on September 08, 2026, and is solely responsible for the information contained therein.